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Abstract 
Progressive  cardiotoxicity  following  treat-
ment with doxorubicin-based chemotherapy in
patients with non-Hodgkin’s lymphoma (NHL)
may  lead  to  late  onset  cardiomyopathy.  So,
early prediction of toxicity can lead to preven-
tion of heart failure in these patients. The aim
of this work was to investigate the role of H-
FABP as an early diagnostic marker of anthra-
cycline-induced cardiac toxicity together with
brain natriuretic peptide (BNP) as an indica-
tion  of  ventricular  dysfunction  in  such
patients. Our study was conducted on 40 NHL
patients who received 6 cycles of a doxorubicin
containing  chemotherapy  protocol  (CHOP),
not exceeding the total allowed dose of doxoru-
bicin (500 mg/m
2). Ten healthy controls were
included in our study. Human heart-type fatty
acid-binding protein (H-FABP) was assessed
24 hours after the first cycle of CHOP. Plasma
levels of BNP were estimated both before start-
ing chemotherapy and after the last cycle of
CHOP. Resting echocardiography was also per-
formed before and at the end of chemo  therapy
cycles. The ejection fraction (EF) of 8 of our
patients decreased below 50% at the end of the
sixth cycle. Elevated levels of both H-FABP and
BNP were found in all patients wth EF below
50% and both markers showed a positive corre-
lation with each other. We concluded that H-
FABP may serve as a reliable early marker for
prediction of cardiomyopathy induced by dox-
orubicin.  Thus,  in  patients  with  elevated  H-
FABP, alternative treatment modalities with no
cardiac toxicity may be considered  in order to
prevent  subsequent  heart  failure  in  these
patients.
Introduction
Anthracyclines are highly efficacious anti-
neoplastic agents but their utility is limited by
progressive cardiotoxicity. They include doxo  -
rubicin,  daunorubicin,  epirubicin  and  idaru-
bicin.
1 Anthracyclines cause a dose-dependent
cardiomyopathy that often leads to congestive
heart failure. Late onset cardiomyopathy can
appear months to years after treatment is com-
pleted.
2 The mechanism underlying cardiotox-
ic effects of anthracyclines is generally accept-
ed to be via formation of free radicals generat-
ed by iron-doxorubicin complexes that damage
cardiac cellular membranes.
3 Cardiac damage
caused by anthracyclines  is cumulative. With
total doses of doxorubicin less than 500 mg/m
2,
heart failure is seen in less than 7% of cases.
4
Human heart fatty acid-binding protein (H-
FABP)  is  a  small  protein  abundant  in  the
cytosol, which is readily released into the cir-
culation following myocardial damage. Recent
studies  in  laboratories  and  the  emergency
department have shown that heart-type fatty
acid-binding protein (H-FABP), a more recent-
ly  developed  cardiac  biomarker,  is  able  to
detect myocardial damage as soon as one hour
after  onset  of  ischemia  and,  therefore,  is
regarded  the  earliest  plasma  marker  avail-
able.
5,6 A  bedside  test  for  H-FABP,  providing
results within 15 min,
7 could potentially reduce
diagnostic uncertainty for patients suspected
of ACS in primary care. Recently, Setsuta and
colleagues reported that elevated levels of H-
FABP were associated with subsequent cardiac
events in patients with chronic heart failure
due to a variety of causes.
8 On the other hand,
brain natriuretic peptide (BNP) is an amino
acid peptide chiefly secreted by the ventricular
myocardium  in  response  to  strain.  Thus,  it
may be viewed as a marker of myocardial load
and the plasma measurement of BNP is being
used increasingly in the diagnosis, prognosis
and  monitoring  of  patients  with  congestive
heart failure.
9,10 Since heart failure is a com-
plex clinical syndrome, a single biochemical
marker may not reflect all of its characteristics.
Thus, the serial and combined measurements
of markers of myocyte injury may open new
perspectives in heart failure. 
8 The aim of our
work was to investigate the value of H-FABP as
an early diagnostic marker of anthracycline-
induced cardiotoxicity together with BNP as an
indicator  of  ventricular  dysfunction  in  non-
Hodgkin’s lymphoma patients receiving doxo  -
rubicin-based chemotherapy.
Subjects and Methods
Our  study  was  conducted  on  40  patients
with non-Hodgkin’s lymphoma who received 6
cycles of an anthracycline containing regimen
(CHOP) with the following doses:
11
Cyclophosphamide: 750 mg/m
2 IV Day 1
Doxorubicin: 50 mg/m
2 IV Day 1
Vincristine: 1.4 mg/m
2 IV Day 1
Prednisone: 100 mg/d PO Days 1-5
This cycle was repeated every 21 days.
Patients’  age  ranged  from  14  to  56  years
with a mean of 36.2±10.02 years. Twenty-two
of them were males, while 18 were females.
Ten age and sex-matched healthy controls with
no history of cardiac problems were included
in our study.
None of our patients had symptoms or signs
of cardiac disease at presentation, nor  had
they  undergone  previous  cardiac  surgery.
Patients with severe hepatic or renal disease
or other medical conditions in which combina-
tion  chemotherapy  may  be  contraindicated
were excluded from our study. Also, patients
with early stage disease (stage I and non-bulky
stage II) who are candidates for involved-field
irradiation in addition to chemotherapy were
excluded.
At  presentation,  full  history  and  clinical
examination,  complete  blood  picture,  bone
marrow examination and lymph node biopsy
were carried out in all patients. Routine labo-
ratory investigations, ECG and echocardiogra-
phy were also performed.
Blood samples were obtained for estimation
of BNP before starting the first cycle of chemo  -
therapy and after completion of the sixth cycle.
Blood  was  withdrawn  for  assessment  of  H-
FABP within 24 hours of administration of dox-
orubicin in the first cycle of CHOP
12 H-FABP
was  measured  utilizing  human  cardiac  fatty
acid-binding  protein  ELISA  test  kit,  Oxis
research catalog number: 11230, Oxis Intern  -
ational Inc., Foster City, CA, USA.
13Re-evalua-
tion of ECHO findings regarding the left ven-
tricular  ejection  fraction  and  parameters  of
diastolic function
14 was carried out after the
end of the sixth cycle of chemo-therapy.
Results
Patients’ data are summarized in Table 1.
The mean age of our patients at presentation
was 36.2±10.02 years. Fifty-five percent were
males, while 45% were females. All patients
had normal ECG findings with no clinical evi-
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dence of heart failure prior to chemotherapy.
After  completing  the  first  cycle  of  CHOP,
plasma levels of H-FABP were found to be ele-
vated in 10 patients. After completion of the
sixth  cycle  of  chemotherapy,  8  of  the  10
patients with elevated H-FABP showed a sig-
nificant reduction in the left ventricular ejec-
tion  fraction  to  levels  below  50%  and  the
reduction in EF showed a significant correla-
tion with H-FABP levels (Figure 1). Six of them
also showed evidence of diastolic dysfunction
in the form of impaired relaxation and an E/A
ratio below 1. Two patients of those with post-
chemotherapy  ejection  fraction  values  less
than 50% had clinical manifestations of heart
failure. Fifteen of our patients (37.5%) showed
evidence of diastolic dysfunction after 6 cycles
of chemotherapy but 3 of them already had E/A
ratios below 1 when evaluated before starting
chemotherapy.  We  divided  our  patients  into
two  groups  according  to  echocardiographic
evidence of  left ventricular systolic dysfunc-
tion  after  the  sixth  cycle  of  chemotherapy
(Table 2): Group I; patients who had left ven-
tricular  ejection  fraction  levels  below  50%;
Group  II;  patients  who  had  no  echocardio-
graphic evidence of heart failure.    
On comparing  the mean  plasma BNP  val-
ues  in  both  groups,  we  found  that  prior  to
chemotherapy, they did not show a significant
difference  (mean  value  group  I  70.28±9.45,
group II 75.62±11.84). After six cycles of che  -
motherapy, both groups differed significantly
as  regards plasma BNP, with the mean value in
group I being 70.4±9.527 and in group II being
260±18.51 (p<0.001). There was also a signifi-
cant  elevation    of    BNP  values  in  group  II
patients after chemotherapy and this elevation
correlated  significantly with the reduced ejec-
tion  fraction  in  these  patients  (Figure  2).
There were no patients in whom clinical car-
diac  failure  occurred  without  an  associated
rise in the BNP level above the threshold value.
From the 10 patients who exhibited elevated H-
FABP levels after the first chemotherapy cycle,
8 also showed  high BNP levels at the end of the
sixth cycle and both biochemical markers cor-
related positively with each other (Figure 3).
Discussion
Cardiotoxicity  leading  to  congestive  heart
failure is a well-known complication of anthra-
cyclines. Biochemical methods to assess and
monitor cardiac function after anthracycline
administration,  if  informative  would  be  of
utmost  value.
15 We  examined  the  diagnostic
role  of  human  heart-type  fatty  acid  binding
protein and brain natriuretic peptide to predict
the impairment of left ventricular function in
NHL patients treated by CHOP. We also studied
the correlations between the plasma concen-
trations of these biomarkers and the function-
al alterations associated with doxorubicin-in  -
duced myocardial damage. A significant corre-
lation  between  the  left  ventricular  ejection
fraction after 6 cycles of CHOP and plasma lev-
els of both HFABP and BNP was found in our
patients. Pichon and colleagues stated that an
infra-clinical  cardiotoxicity  of  anthracyclines
as defined by BNP elevation is frequent but
reversible  and  that  patients  who  developed
heart  failure  showed  a  continuous  BNP
increase and concentrations over 100 ng/mL.
16
On the other hand, Daugaard and colleagues
concluded that in spite of correlations between
peptide  concentrations  and  reduced  ejection
fraction  values,  neither  baseline  levels  nor
serial measurements can safely substitute EF
monitoring in patients undergoing anthracy-
cline  therapy.
10  Brain  natriuretic  peptide
(BNP) was originally discovered in the porcine
brain but was subsequently found to be pre-
dominantly a cardiac hormone.
17 Unlike atrial
Table 1. Biochemical markers and ECHO findings in our patients.
N. Minimum  Maximum Mean
Age 40 14 56 36.2± 10.02
BNP before chemotherapy (pg/mL) 40 50  89 71.35±10.04
BNP after chemotherapy (pg/mL) 40 50 280 108.32±77.66
H-FABP (ng/mL) 40 8 30 17.25±6.44
EF before chemotherapy (%) 40 58 72 65.57±4.04
EF after chemotherapy (%) 40 40 70 61.4±9.79
Figure  1.  Correlation
between  ejection  frac-
tion  after  6  cycles  of
CHOP and HFABP.
HFABP
R = - 0.836
p<0.001
Table 2. Comparison between group I and II patients as regards BNP and H-FABP.
N. Mean T p
Age GI 32 38.84±10.02 -1.79 0.081
GII 8 41.75±8.44
BNP before chemotherapy (pg/mL) 
GI 32 70.28±9.45 -1.185 0.265
GII 8 75.62±11.8
BNP after chemotherapy (pg/mL)
GI 32 70.4±9.52 -28.048 0.000*
GII 8 260±18.5
H-FABP (ng/mL) 
GI 32 13.84±2.68 -13.103 0.000*
GII 8 27.15±2.53
EF before chemotherapy (%)
GI 32 65.84±4.14 0.903 0.384
GII 8 64.5±3.66
EF after chemotherapy (%)
GI 32 65.65±5.02 15.47 0.000*
GII 8 44.37±2.97
* p Significant . GI: Patients with post chemotherapy EF above 50% . GII: Patients with post- chemotherapy EF below 50%.natriuretic peptide (ANP), which is secreted by
the atria in response to increased atrial pres-
sure, BNP is derived chiefly from the cardiac
ventricles in response to ventricular stresses.
18
The plasma levels of both peptides are inverse-
ly correlated with measures of cardiac function
and recent studies have shown BNP to be a
more sensitive marker of cardiac impairment
than ANP.
19, 20 Raised plasma BNP levels have
previously  been  shown  to  herald  the  clinical
picture of cardiac failure by days to weeks.
21
Various guidelines based on changes in systolic
and  diastolic  left  ventricular  function  deter-
mined either by ECHO or by radionuclideven-
triculography  (RVG)  have  been  proposed  for
monitoring  patients  receiving  anthracycline
therapy. The advantages of ECHO over RVG are
better availability, lower costs and lack of expo-
sure to ionizing radiation.
16Although H-FABP is
viewed as a marker of myocyte injury and BNP
is considered  indicative of ventricular strain,
the finding that both markers correlated with
each  other  in  our  patients  shows  that  some
degree  of  myocyte  injury  is  associated  with
increased ventricular load. It is well-known that
myocardial structure is also altered in conges-
tive heart failure (CHF). Non-contiguous areas
of myocardial cell death and foci of replacement
fibrosis are typical morphological changes in
advanced  CHF.  Therefore,  cytosolic  proteins
may be released into the circulation through
leakage due to increased permeability of the
membranes  of  injured  myocytes.
22 Thus,  the
present  study  highlights  the  practical  impor-
tance of measuring  some biochemical markers
such as  plasma  H-FABP and BNP to monitor
left ventricular dysfunction in patients receiv-
ing anthracycline therapy as an early indication
of subclinical cardiotoxicity.
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